deaths (OS)

Extensive stage SCLC (Es-SCLC) - 1st Line (L1) Extensive stage SCLC (Es-SCLC) Extensive stage SCLC (Es-SCLC) - 1st Line (L1)

versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC 1 0.80 [0.65; 0.99], 1 RCT, I2=0%
unassessable degree of certainty